Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>AEON Biopharma is a clinical-stage, specialty pharmaceutical company developing a Botox biosimilar.</li><li>In partnership with Daewoong, it is conducting analytical work to demonstrate biosimilarity for ABP-450.</li><li>Following a Type 2b meeting with the FDA, we expect 2027 PD & bridging studies to support the Section 351(k) BLA package for approval.</li></ul>

AEON Biopharma is a clinical-stage, specialty pharmaceutical company developing a Botox biosimilar.In partnership with Daewoong, it is conducting analytical work to demonstrate biosimilarity for ABP-450.Following a Type 2b meeting with the FDA, we expect 2027 PD & bridging studies to support the Section 351(k) BLA package for approval.

AEON: Initiating Coverage - Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Cross Asset Strategy

<ul><li>Technically, the SET Index is expected to move in a sideways-down pattern, with the support at 1,352/1,345 points and the resistance at 1,370/1,375 points.</li><li>In the medium term, the index remains in a large sideways range between 1,273 and 1,716 points.</li><li>Investment strategy: It is recommended to wait for a new buy signal, which requires the formation of a higher high and higher low pattern.</li></ul>

Technically, the SET Index is expected to move in a sideways-down pattern, with the support at 1,352/1,345 points and the resistance at 1,370/1,375 points.In the medium term, the index remains in a large sideways range between 1,273 and 1,716 points.Investment strategy: It is recommended to wait for a new buy signal, which requires the formation of a higher high and higher low pattern.

United States

AEON Biopharma, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on developing novel and proprietary treatment paradigms to improve patient outcomes of debilitating medical conditions. AEON Biopharma serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AEON Biopharma Inc (AEON US)

AEON: Initiating Coverage - Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

AEON Biopharma is a clinical-stage, specialty pharmaceutical company developing a Botox biosimilar. In partnership with Daewoong, it is conducting...

Zacks Small Cap Research

Today's Dominant Ideas

Technically, the SET Index is expected to move in a sideways-down pattern, with the support at 1,352/1,345 points and the resistance at...

Krungthai XSpring

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)